FDA NDC
Glyxambi
This name is from the loaded FDA file.
Source: FDA NDC Directory, live from openFDA. Publisher page
- NDC
- 0597-0164
- Proprietary name
- Glyxambi
- Nonproprietary name
- empagliflozin and linagliptin
- Labeler
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Dosage form
- TABLET, FILM COATED
- Strength
- 25 mg/1
Run it in Rivvi
Which 2027 plans near you dropped or restricted empagliflozin and linagliptin?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan, from the CMS Part D files.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.